Not only parents but the doctors prescribing the drug would prefer zero side effects for their patients. Roaccutane is so toxic that I'd image doctors would push for a combination of a topical cream with a less toxic drug first so there is definitely a place for BTX 1503 even if it can't match Roaccutane's efficacy.
There will always be a panic after a mixed announcement. It would have been nice to get clear results but at least it wasn't a complete failure and we're still in the race.
Ann: Botanix Announces BTX 1503 Data and Progression to Phase 3, page-286
-
- There are more pages in this discussion • 117 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
38.0¢ |
Change
0.055(16.9%) |
Mkt cap ! $687.8M | |||
| Open | High | Low | Value | Volume |
| 33.0¢ | 38.0¢ | 33.0¢ | $7.103M | 19.63M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 134000 | 37.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 38.0¢ | 650314 | 19 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| BOT (ASX) Chart |